The United Laboratories International Holdings Limited (HKG:3933)

Market Cap	18.05B -31.9%
Revenue (ttm)	14.70B -4.0%
Net Income	2.32B -21.6%
EPS	1.23 -24.4%
Shares Out	1.97B
PE Ratio	7.43
Forward PE	10.65
Dividend	0.49 (5.25%)
Ex-Dividend Date	Jul 7, 2026

Volume	10,912,240
Open	9.10
Previous Close	9.27
Day's Range	9.00 - 9.39
52-Week Range	7.98 - 17.98
Beta	0.29
Analysts	Strong Buy
Price Target	15.64 (+70.93%)
Earnings Date	Aug 28, 2026

About HKG:3933

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers amoxicillin products; insulin series, antibiotics, and ophthalmic products; and veterinary drugs. It also provides 6-aminopenicillanic acid and penicillin G potassium products. In addition, the company provides endocrine and metabolism, anti-...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 18,000
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3933

Financial Performance

In 2025, HKG:3933's revenue was 13.21 billion, a decrease of -3.99% compared to the previous year's 13.76 billion. Earnings were 2.09 billion, a decrease of -21.57%.

Financial numbers in CNY

Analyst Summary

According to 9 analysts, the average rating for 3933 stock is "Strong Buy." The 12-month stock price target is $15.64, which is an increase of 70.93% from the latest price.

Price Target

$15.64

(70.93% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 21, 2026

Data Sources Report a data error